[1]熊乙霓,郭旭,陈明明.清肺养阴益气汤对晚期非小细胞肺癌化疗减毒增效作用及对患者中医证候和机体免疫功能的影响[J].陕西中医,2025,46(10):1366-1370.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.013]
　XIONG Yini,GUO Xu,CHEN Mingming.Effect of Qingfei Yangyin Yiqi decoction on reducing toxicity and enhancing efficacy of chemotherapy in advanced non-small cell lung cancer and its impact on patients’ traditional Chinese medicine syndrome and immune function[J].,2025,46(10):1366-1370.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.013]
点击复制

清肺养阴益气汤对晚期非小细胞肺癌化疗减毒增效作用及对患者中医证候和机体免疫功能的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年10期
页码:
1366-1370
栏目:
临床研究
出版日期:
2025-10-05

文章信息/Info

Title:
Effect of Qingfei Yangyin Yiqi decoction on reducing toxicity and enhancing efficacy of chemotherapy in advanced non-small cell lung cancer and its impact on patients’ traditional Chinese medicine syndrome and immune function
作者:
熊乙霓1; 郭旭1; 陈明明2
（1.遂宁市中医院肿瘤科，四川 遂宁 629000；2.遂宁市中医院治未病科，四川 遂宁 629000）
Author(s):
XIONG Yini1; GUO Xu1; CHEN Mingming2
（1.Department of Oncology,Suining Hospital of Traditional Chinese Medicine,Suining 629000，China；2.Department of Preventive Medicine,Suining Municipal Hospital of Traditional Chinese Medicine,Suining 629000，China）
关键词:
晚期非小细胞肺癌; 清肺养阴益气汤; 化疗; 减毒增效; 中医证候; 免疫功能
Keywords:
Advanced non-small cell lung cancer; Qingfei Yangyin Yiqi decoction; Chemotherapy; Reduced toxicity and increased efficiency; Traditional Chinese medicine syndrome; Immune function
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2025.10.013
文献标志码:
A
摘要:
目的：探讨清肺养阴益气汤对晚期非小细胞肺癌化疗减毒增效的作用及对患者中医证候和机体免疫功能的影响。方法：取符合纳入标准接受化疗的晚期非小细胞肺癌受试者，随机分组建立对照组（单纯化疗方案）和联合组（在对照组基础上联合清肺养阴益气汤治疗）。观察患者治疗后临床疗效和中医证候积分及症状积分；血清肿瘤标志物癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）等；细胞因子白介素（IL）-1β、IL-6和IL-10，以及免疫功能检测比较及两组安全性和不良反应。结果：联合组的客观有效率为56.41%，明显高于对照组的33.33%，差异有统计学意义（P<0.05）。联合组的中医主症、次症、舌象积分明显高于对照组，差异有统计学意义（均P<0.05）。治疗后两组CEA、NSE和鳞状细胞癌抗原（SCCAg），IL-6、IL-1β、CD8+水平均较治疗前下降；IL-10、CD3+和CD4+水平及CD4+/CD8+较治疗前上升（均P<0.05）；且治疗后联合组的CEA、NSE、SCCAg、IL-6、IL-1β及CD8+水平均低于对照组；IL-10、CD3+、CD4+及CD4+/CD8+均高于对照组，差异有统计学意义（均P<0.05）。治疗期间联合组的恶心呕吐、腹泻、血小板减少和骨髓抑制率明显低于对照组，差异有统计学意义（均P<0.05）。结论：对于晚期非小细胞肺癌化疗患者，清肺养阴益气汤可发挥减毒增效的作用，并且可改善患者中医证候，增强机体免疫功能，减缓炎症反应，提升患者生活质量。
Abstract:
Objective:To clarify the effect of Qingfei Yangyin Yiqi decoction on reducing toxicity and enhancing efficacy of chemotherapy for advanced non-small cell lung cancer,as well as its impact on patients’ traditional Chinese medicine syndromes and immune function.Methods:This study included advanced non-small cell lung cancer subjects who met the inclusion criteria for chemotherapy and randomly divide them into a control group (with a simple chemotherapy regimen) and a combined group (treated with Qingfei Yangyin Yiqi decoction in addition to intervention in the control group).The outcome measures included:comparison of clinical efficacy and specific scores of traditional Chinese medicine syndrome scores;serum tumor markers of carcinoembryonic antigen (CEA),neuron-specific enolase (NSE),etc.;cytokines of interleukin (IL)-1β,IL-6 and IL-10,and immune function levels;and safety revealed by adverse reactions.Results:The objective response rate of the combined group was 56.41%,significantly higher than that of 33.33% in the control group,and the difference was statistically significant (P<0.05).The scores of traditional Chinese medicine main symptoms,secondary symptoms,and tongue symptoms in the combined group were significantly higher than those in the control group,and the differences were statistically significant (all P<0.05).Furthermore,after treatment,the levels of CEA,NSE,squamous cell carcinoma antigen (SCCAg),IL-6 and IL-1β,and CD8+ in both groups decreased compared to before treatment;while IL-10,CD3+,CD4+ levels,and CD4+/CD8+ were increased compared to before treatment (all P<0.05);moreover,after treatment,the levels of CEA,NSE,SCCAg,IL-6 and IL-1β,and CD8+ in the combination group were lower than those in the control group;while IL-10,CD3+,CD4+ levels,and CD4+/CD8+ were higher than those in the control group,with statistically significant differences (all P<0.05).During the treatment period,the rates of nausea and vomiting,diarrhea,thrombocytopenia,and myelosuppression in the combined group were significantly lower than those in the control group,and the differences were statistically significant (all P<0.05).Conclusion:For patients with advanced non-small cell lung cancer undergoing chemotherapy,Qingfei Yangyin Yiqi decoction can play roles in reducing toxicity and increasing efficiency,which can improve traditional Chinese medicine syndromes,enhance immune function,slow down inflammatory reactions,and improve patients’ quality of life.This therapeutic scheme is safe and effective.

参考文献/References:

[1]钱源源,蔡旭东,胡晓炜,等.2010—2020年中国城乡人口老龄化对四种主要癌症负担的量化研究[J].医学理论与实践,2024,37(12):1998-2002.
[2]SHIRAISHI Y,KISHIMOTO J,SUGAWARA S,et al.Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer:A phase 3 randomized clinical trial[J].JAMA Oncol，2024，10(3):315-324.
[3]杨金月,孙宏新,施艾每,等.基于数据挖掘分析孙宏新治疗肺癌用药规律[J].陕西中医,2024,45(9):1278-1282.
[4]YIN X,LI Y,WANG H,et al.Small cell lung cancer transformation:From pathogenesis to treatment[J].Semin Cancer Biol，2022，86(2):595-606.
[5]周家香,吴春芝,冯芳,等.康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响[J].陕西医学杂志,2024,53(6):818-822.
[6]ZHOU C,HU Y,ARKANIA E,et al.A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004) [J].Cancer Cell，2024，42(2):198-208.
[7]赵宣,闫红倩,裴玉蓁.理肺解毒益髓汤对晚期肺癌化疗增效减毒作用及对中医证候积分、细胞因子和免疫功能的影响[J].辽宁中医杂志,2024,51(10):116-120.
[8]刘莲芳,卢子涵,胡霞,等.益气养阴解毒方对Lewis肺癌小鼠的免疫调节及抗肿瘤作用[J].南京中医药大学学报,2025,41(1):95-101.
[9]李昊.加味百合固金汤联合大承气汤对晚期肺癌合并肺炎患者炎症因子的影响[J].辽宁中医杂志,2020,47(4):101-104.
[10] 王倩,蒋思雨,刘倩希,等.加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医,2024,45(8):1048-1051.
[11]陈鑫,骆洪雁,高晶,等.清肺益气汤联合GP方案治疗晚期非小细胞肺癌的疗效观察[J].河北医药,2020,42(3):335-339.
[12]梁勇,王鹏,徐明.清肺化痰汤治疗痰热郁肺证老年晚期非小细胞肺癌患者的临床疗效及对其生活质量、血清癌胚抗原、神经元特异性烯醇化酶、细胞角质素片段抗原水平的影响[J].世界中西医结合杂志,2024,19(8):1603-1607.
[13]林洪生.恶性肿瘤中医诊疗指南[M].北京：人民卫生出版社,2014:25.
[14]韩宝惠,高树庚,林冬梅,等.中华医学会肺癌临床诊疗指南(2019版)[J].中华肿瘤杂志,2020,42(4):257-287.
[15]XU J,WAN R,CAI Y,et al.Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer[J].Cancer Cell，2024，42(9):1598-1613.
[16]HARATANI K,HAYASHI H,CHIBA Y,et al.Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer[J].JAMA Oncol，2018，4(3):374-378.
[17]胡帅航,田培裕,张孝刚,等.从“水精四布”论治肺癌[J].中医学报,2021,36(7):1400-1403.
[18]陈滨海,张雅丽,李晓娟,等.基于痰毒病机的晚期非小细胞肺癌证型分布规律研究[J].中华中医药杂志,2020,35(4):1976-1979.
[19]NOSAKI K,SAKA H,HOSOMI Y,et al.Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer:Pooled analysis from the KEYNOTE-010,KEYNOTE-024,and KEYNOTE-042 studies[J].Lung Cancer，2019，135:188-195.
[20]宁彩红,彭坷平,田桂湘,等.益气养阴解毒方加减用于放化疗后气阴两虚、毒热蕴肺证鼻咽癌患者的增效减毒效应观察[J].湖南中医药大学学报,2025,45(1):158-163.
[21]闫红倩,裴玉蓁,耿立梅,等.理肺解毒益髓汤对晚期肺癌化疗的增效减毒作用及其机制研究[J].中国医学创新,2024,21(27):5-9.
[22]高颖,孟蕾.双水平无创正压通气对老年中晚期肺癌并心力衰竭患者心肺功能及心肌损伤标志物的影响[J].陕西医学杂志,2023,52(4):428-432.
[23]陆凯娟,徐佳丽,张娟,等.养肺益气汤联合载药微球支气管动脉化疗在非小细胞肺癌治疗中的临床效果分析[J].中外医学研究,2024,22(6):18-21.
[24]朱银兴,林瑜,郑黄珽,等.养阴益气汤联合化疗治疗中晚期非小细胞肺癌近期疗效及对T细胞亚群、VEGF和IL-6表达影响[J].浙江中西医结合杂志,2021,31(9):828-830.
[25]赵军.滋阴解毒养肺汤联合GP化疗治疗Ⅲ及Ⅳ期肺癌的疗效观察[J].当代医学,2022,28(4):182-184.

相似文献/References:

[1]张羽飞,朱鸿帆,吴 申,等.复方皂刺汤联合PP方案治疗晚期非小细胞肺癌疗效及安全性分析*[J].陕西中医,2020,(1):60.

备注/Memo

备注/Memo:
四川省中医药管理局科学技术研究专项课题（2024MS368）
更新日期/Last Update: 2025-10-10